Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
Former Voyager CEO Andre Turenne makes a comeback with Atlas-backed covalent drug biotech
3 years ago
Startups
A French biotech nabs Series A to see if it can carve a role in the ADC space
3 years ago
Startups
With data from nine-patient study, VectivBio raises $125M ahead of lead program's big readout
3 years ago
R&D
J&J and Sanofi-partnered oral delivery biotech raises $26M on latest offering
3 years ago
New-look Fred Hutch snags slice of Bezos fortune for 10 years of research
3 years ago
People
Cell/Gene Tx
After bringing his total raise for Odyssey to $386M, Gary Glick is ready to start inking deals. Just watch
3 years ago
Now with positive PhI data, DICE goes after public offering in search of $250M
3 years ago
With help from Lululemon founder’s venture philanthropy, Vita adds second muscular dystrophy indication to lineup
3 years ago
R&D
Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t
3 years ago
Deals
Pharma
Michael Ehlers and Romesh Subramanian launch biotech with $50M, sea squirt-inspired RNA-editing tech
3 years ago
Startups
A year after debuting with $500M, Bob Nelsen's Really Big Neuroscience Company raises a really not-as-big Series B
3 years ago
After two CRLs, FDA approves scPharmaceuticals' drug-device as biotech nabs $100M to fund launch
3 years ago
FDA+
A liver disease upstart with some global connections and a new R&D strategy reaps a $30M launch round
3 years ago
R&D
Oncolytic virus experts at Replimune reload with $200M loan as biotech collects clinical data
3 years ago
Armed with $125M, Nested Therapeutics debuts with plan to jumpstart next-gen precision oncology efforts
3 years ago
Startups
California dreamin': Red Tree VC shop takes Boston funds' spinout approach to West Coast
3 years ago
Startups
After Covid setback, Valneva lines up $100M for Pfizer-allied Lyme disease PhIII
3 years ago
Pharma
Coronavirus
A dozen years in the making, a UC Berkeley spinout nabs funds to take on the eye
3 years ago
Startups
Amylyx snatched the landmark approval for its ALS drug. Now it’s seeking cash to foot the launch bill
3 years ago
Looking to push CAR-T in solid tumors, Bay Area biotech goes public in SPAC flip — with slight name change
3 years ago
Deals
Tiny Vergent seals modest Series B in pursuit of cancer imaging agent
3 years ago
R&D
A year and a half after Cellarity raised $123M, the Flagship biotech is back — and it's ready to pick out candidates
3 years ago
Startups
George Church, Wyss scientists and Northpond challenge conventional RNA manufacturing with new biotech
3 years ago
People
Cell/Gene Tx
Recently out-of-stealth neuroscience outfit unveils cash raise, more details on Lilly, Northwestern programs
3 years ago
R&D
First page
Previous page
45
46
47
48
49
50
51
Next page
Last page